Amundi Has $66.93 Million Stock Position in Hologic, Inc. $HOLX

Key Points

• Amundi has reduced its holdings in Hologic, Inc. by 28.1%, selling 423,165 shares, and now owns approximately 0.49% of the company, valued at $66.93 million.
• Several institutional investors, including Victory Capital Management and Invesco, have increased their stakes in Hologic, demonstrating confidence in the company’s performance.
• Hologic reported earnings of $1.08 per share for the last quarter, surpassing analyst expectations and showcasing a 1.2% growth in revenue year-over-year.

Amundi cut its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 28.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,084,934 shares of the medical equipment provider's stock after selling 423,165 shares during the quarter. Amundi owned approximately 0.49% of Hologic worth $66,930,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new position in Hologic during the 1st quarter valued at approximately $34,000. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Hologic in the first quarter valued at $42,000. Raiffeisen Bank International AG acquired a new position in shares of Hologic during the fourth quarter valued at $49,000. Allworth Financial LP grew its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 722 shares during the period. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HOLX. Evercore ISI boosted their target price on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and boosted their price target for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, Citigroup raised Hologic from a "neutral" rating to a "buy" rating and increased their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Price Performance

NASDAQ:HOLX traded up $0.18 during trading hours on Tuesday, reaching $66.72. 1,186,914 shares of the company's stock were exchanged, compared to its average volume of 1,570,787. The company has a market capitalization of $14.84 billion, a P/E ratio of 27.68, a price-to-earnings-growth ratio of 2.42 and a beta of 0.57. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The business's 50-day simple moving average is $66.40 and its two-hundred day simple moving average is $62.63.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the prior year, the company earned $1.06 earnings per share. The firm's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.